Zacks: Brokerages Set $44.00 Target Price for National Research Co. (NRCIB)
Shares of National Research Co. (NASDAQ:NRCIB) have earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Brokerages have set a 1 year consensus price target of $44.00 for the company and are anticipating that the company will post $0.27 EPS for the current quarter, according to Zacks. Zacks has also assigned National Research an industry rank of 115 out of 265 based on the ratings given to related companies.
National Research (NASDAQ NRCIB) traded down $1.35 during trading hours on Thursday, reaching $52.13. The company’s stock had a trading volume of 5,600 shares, compared to its average volume of 3,067. The company has a market capitalization of $1,309.30, a price-to-earnings ratio of 75.32 and a beta of 0.07. National Research has a 12-month low of $38.50 and a 12-month high of $57.21.
National Research Company Profile
National Research Corporation provides analytics and insights for the patient and employee experience in serving the healthcare providers, payers, and other healthcare organizations in the United States and Canada. Its portfolio of subscription-based solutions offer information and analysis services in a range of elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for National Research Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Co. and related companies with MarketBeat.com's FREE daily email newsletter.